Boston Scientific Corporation is on the verge of releasing its financial results for the fourth quarter, with market participants eagerly awaiting the figures. Expectations are high, with financial analysts projecting a notable surge in both earnings per share and overall revenue, underscoring the company's robust performance in the medical device sector. This anticipation comes amidst recent developments, including a product alert that briefly impacted market sentiment.
The Marlborough, Massachusetts-based medical technology giant, trading on the New York Stock Exchange under the ticker BSX, is scheduled to unveil its fourth-quarter earnings report on Wednesday, February 4th, prior to the opening of trading. Industry experts have meticulously analyzed the company's financial trajectory and current market position, culminating in revised forecasts. The consensus among these analysts points to an expected earnings per share of 78 cents, a significant uplift from the 70 cents recorded during the same period in the previous year. Furthermore, projections for the company's quarterly revenue indicate a robust $5.28 billion, a substantial increase from the $4.56 billion reported in the prior year, as detailed by Benzinga Pro.
In the preceding month, the U.S. Food and Drug Administration (FDA) acknowledged a notice from Boston Scientific regarding the voluntary withdrawal of specific AXIOS stents and their accompanying electrocautery-enhanced delivery systems. This action was prompted by identified concerns that these devices could potentially pose considerable risks to patients during medical procedures. Following this announcement, Boston Scientific's stock experienced a slight dip, closing at $91.62 on Tuesday, representing a 0.3% decrease. Despite this, the broader outlook from financial experts remains largely positive.
Leading Wall Street analysts have provided their updated assessments and price targets for Boston Scientific. For instance, Barclays analyst Matt Miksic reiterated an Overweight rating but adjusted the price target from $136 to $124 on February 3, 2026. Oppenheimer's Suraj Kalia maintained an Outperform rating, lowering the price target from $125 to $100 on January 16, 2026. Truist Securities analyst Richard Newitter kept a Buy rating, reducing the price target from $130 to $120 on December 18, 2025. Canaccord Genuity analyst William Plovanic also maintained a Buy rating, with a minor adjustment of the price target from $132 to $131 on December 17, 2025. Conversely, RBC Capital analyst Shagun Singh maintained an Outperform rating and increased the price target from $125 to $130 on December 17, 2025. These varied adjustments reflect a dynamic analytical landscape as the earnings release approaches.
The forthcoming earnings announcement will provide crucial insights into Boston Scientific's financial health and operational efficiency. Investors and market watchers will be closely scrutinizing the report for details on revenue streams, profitability, and any updates regarding the product recall. The company's ability to meet or exceed analyst expectations will be a key determinant of its short-term stock performance and long-term market perception.
